News & Updates
Filter by Specialty:
Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax
The bivalent mRNA-1273.214 booster vaccine provides superior immunogenicity compared with the original COVID-19 mRNA-1273 vaccine in a phase III study, according to an expert who presented at ECCMID 2023.
Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax
27 Apr 2023SARS-CoV-2 infection poses heightened risk of diabetes
SARS-CoV-2 infection puts individuals at increased risk of developing diabetes, contributing to between 3 percent and 5 percent excess burden of diabetes at a population level, as reported in a study.
SARS-CoV-2 infection poses heightened risk of diabetes
26 Apr 2023EAGLE trials herald new era for uncomplicated UTI treatment
Oral gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action, showed favourable signals for the treatment of uncomplicated urinary tract infections (uUTIs), according to the results of two phase III trials.
EAGLE trials herald new era for uncomplicated UTI treatment
25 Apr 2023Pregnancy a risk factor for COVID-19 among unvaccinated women
Pregnant women who remain unvaccinated from COVID-19 are at increased risk of contracting COVID-19 when compared with unvaccinated nonpregnant women, as reported in a study for the Philippines.
Pregnancy a risk factor for COVID-19 among unvaccinated women
24 Apr 2023Severe COVID patients 16 times more likely to experience V-tach
Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia (V-tach) within 6 months following discharge compared with matched controls without severe infection in a Swedish case-control study presented at EHRA 2023.
Severe COVID patients 16 times more likely to experience V-tach
24 Apr 2023Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection
Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.